It is the first and only treatment that has been approved for geographic atrophy, a leading cause of blindness, according to a Feb. 17 news release.
Syfovre is set to be available to specialty distributors and pharmacies across the country in March.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
